Completed PHASE4 INTERVENTIONAL 2-arm NCT01303874

Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) (EMPIRE)

A Multicentre Randomised Trial Of Etanercept And Methotrexate To Induce Remission In Early Inflammatory Arthritis

Sponsor: University of Leeds

Conditions Inflammatory Arthritis Rheumatoid Arthritis

Updated 5 times since 2017 Last updated: Oct 30, 2019 Started: Sep 30, 2006 Primary completion: Nov 5, 2010 Completion: Nov 5, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01303874, this PHASE4 trial focuses on Inflammatory Arthritis and Rheumatoid Arthritis and remains completed. Sponsored by University of Leeds, it has been updated 5 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Dec 2019 — Jan 2021 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jan 2017 — Dec 2019 [monthly]

Unknown Status PHASE4

First recorded

Sep 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Leeds

Data source: University of Leeds

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leeds, United Kingdom